Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ido-BR1 is a naturally occurring iminosugar small molecule developed by Phytoquest, primarily isolated from *Cucumis sativus* (cucumber). It functions as a glycosidase inhibitor with significant anti-inflammatory activity. Marketed under the brand name Q-Actin as a dietary supplement, it has been clinically shown to improve joint function and reduce pain in patients with osteoarthritis. Beyond joint health, Phytoquest is investigating ido-BR1 for its neuroprotective properties and potential in maintaining brain health, as iminosugars can cross the blood-brain barrier and modulate various cellular pathways involved in neuroinflammation and protein folding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ido-BR1.